Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall. sjo [Internet]. 2026 Jun. 19 [cited 2026 Jul. 30];8(2):478-85. Available from: https://www.sriwijayaopthalmology.com/index.php/sjo/article/view/137